Last reviewed · How we verify
erenumab-aooe
erenumab-aooe is a CGRP monoclonal antibody antagonist Small molecule drug developed by Amgen. It is currently FDA-approved for Migraine prevention in adults, Chronic migraine prevention. Also known as: Aimovig®, Aimovig.
Erenumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
Erenumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Migraine prevention in adults, Chronic migraine prevention.
At a glance
| Generic name | erenumab-aooe |
|---|---|
| Also known as | Aimovig®, Aimovig |
| Sponsor | Amgen |
| Drug class | CGRP monoclonal antibody antagonist |
| Target | Calcitonin gene-related peptide (CGRP) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
CGRP is released during migraine attacks and contributes to pain signaling and neuroinflammation. By neutralizing CGRP, erenumab reduces the frequency and severity of migraines. This mechanism represents a novel approach targeting the underlying biology of migraine rather than just treating acute symptoms.
Approved indications
- Migraine prevention in adults
- Chronic migraine prevention
Common side effects
- Injection site reactions
- Constipation
- Nasopharyngitis
- Muscle cramps
Key clinical trials
- Aimovig Pregnancy Exposure Registry
- Screening Trial for Pain Relief in Schwannomatosis (STARFISH) (PHASE2)
- Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder (PHASE2)
- Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE) (PHASE2)
- Erenumab-aooe for the Management of Trigeminal Neuropathic Pain. (PHASE2)
- Efficacy of Erenumab on Functional Impact of Migraine (PHASE4)
- Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- erenumab-aooe CI brief — competitive landscape report
- erenumab-aooe updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about erenumab-aooe
What is erenumab-aooe?
How does erenumab-aooe work?
What is erenumab-aooe used for?
Who makes erenumab-aooe?
Is erenumab-aooe also known as anything else?
What drug class is erenumab-aooe in?
What development phase is erenumab-aooe in?
What are the side effects of erenumab-aooe?
What does erenumab-aooe target?
Related
- Drug class: All CGRP monoclonal antibody antagonist drugs
- Target: All drugs targeting Calcitonin gene-related peptide (CGRP)
- Manufacturer: Amgen — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Migraine prevention in adults
- Indication: Drugs for Chronic migraine prevention
- Also known as: Aimovig®, Aimovig
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing